Literature DB >> 15541003

Tau aggregates are abnormally phosphorylated in inclusion body myositis and have an immunoelectrophoretic profile distinct from other tauopathies.

C-A Maurage1, T Bussière, N Sergeant, A Ghesteem, D Figarella-Branger, M-M Ruchoux, J-F Pellissier, A Delacourte.   

Abstract

Sporadic inclusion body myositis (s-IBM) is the most frequent progressive acquired inflammatory myopathy in people older than 50 years. Abnormal aggregates of 'Alzheimer's proteins', including tau proteins, have been previously demonstrated in s-IBM. In the present study, we have investigated by immunohistochemistry and immunoblotting analysis the presence of tau proteins in muscle biopsy samples from patients with s-IBM and other myopathies with rimmed vacuoles, using newly developed antibodies raised against tau protein epitopes found in Alzheimer's disease brain. Tau immunoreactivity was shown in rimmed vacuoles or inclusions, preferentially with antibodies directed against phosphorylated carboxy-terminal epitopes of tau proteins. Cytoplasmic reactivity was also demonstrated in atrophic, nonvacuolated fibres, as well as in non-necrotic fibres invaded by inflammatory cells. Abnormally phosphorylated tau aggregates were also found in other compartments of the muscle fibre in s-IBM and other myopathies. Tau immunoblotting showed an electrophorectic profile of a doublet within the range of 60-62 kDa isovariants, which was different from tauopathies of the central nervous system. Finally, the unique pattern of immunoreactivity of s-IBM samples towards anti-tau antibodies is a new clue to a possible distinct subclass of peripheral tauopathy, different from the tauopathies of the central nervous system.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15541003     DOI: 10.1111/j.1365-2990.2004.00577.x

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  12 in total

1.  Genetically augmenting Abeta42 levels in skeletal muscle exacerbates inclusion body myositis-like pathology and motor deficits in transgenic mice.

Authors:  Masashi Kitazawa; Kim N Green; Antonella Caccamo; Frank M LaFerla
Journal:  Am J Pathol       Date:  2006-06       Impact factor: 4.307

Review 2.  Myositis Mimics.

Authors:  E Harlan Michelle; Andrew L Mammen
Journal:  Curr Rheumatol Rep       Date:  2015-10       Impact factor: 4.592

3.  Generation and characterization of a tractable C. elegans model of tauopathy.

Authors:  Joshua C Russell; Haoyi Lei; Rahul K Chaliparambil; Sarah Fish; Susan M Markiewicz; Ting-I Lee; Anushka Noori; Matt Kaeberlein
Journal:  Geroscience       Date:  2021-09-18       Impact factor: 7.581

4.  Development of AD-Like Pathology in Skeletal Muscle.

Authors:  X Chen; N M Miller; Z Afghah; J D Geiger
Journal:  J Parkinsons Dis Alzheimers Dis       Date:  2019-04-02

5.  Casein kinase 1 alpha associates with the tau-bearing lesions of inclusion body myositis.

Authors:  Theresa J Kannanayakal; Jerry R Mendell; Jeff Kuret
Journal:  Neurosci Lett       Date:  2007-12-15       Impact factor: 3.046

Review 6.  Theories of the pathogenesis of inclusion body myositis.

Authors:  Steven A Greenberg
Journal:  Curr Rheumatol Rep       Date:  2010-06       Impact factor: 4.686

Review 7.  Regulation of human MAPT gene expression.

Authors:  Marie-Laure Caillet-Boudin; Luc Buée; Nicolas Sergeant; Bruno Lefebvre
Journal:  Mol Neurodegener       Date:  2015-07-14       Impact factor: 14.195

8.  How citation distortions create unfounded authority: analysis of a citation network.

Authors:  Steven A Greenberg
Journal:  BMJ       Date:  2009-07-20

9.  Altered Blood Biomarker Profiles in Athletes with a History of Repetitive Head Impacts.

Authors:  Alex P Di Battista; Shawn G Rhind; Doug Richards; Nathan Churchill; Andrew J Baker; Michael G Hutchison
Journal:  PLoS One       Date:  2016-07-26       Impact factor: 3.240

Review 10.  Sporadic inclusion body myositis: the genetic contributions to the pathogenesis.

Authors:  Qiang Gang; Conceição Bettencourt; Pedro Machado; Michael G Hanna; Henry Houlden
Journal:  Orphanet J Rare Dis       Date:  2014-06-19       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.